Piramal Pharma Solutions y NP2 completan la fase de desarrollo de ciclofosfamida el próximo mes
Piramal y NP2 tienen previsto finalizar este mes la fase de desarrollo de ciclofosfamida, un fármaco genérico contra el cáncer. Las actividades de desarrollo y...
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- FOUNDERS: HELENA RUBINSTEIN - Nuevo documental dedicado a la mujer que inventó la belleza
- Estudio de Nielsen IQ a consumidores europeos
- Fresenius completa la adquisición de mAbxience, creando una plataforma más sólida para la futura expansión de su cartera de productos
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →